Compare · LBGJ vs TMO
LBGJ vs TMO
Side-by-side comparison of Li Bang International Corporation Inc. (LBGJ) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LBGJ and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $257.53B, about 223761.9x LBGJ ($1.2M).
- Over the past year, LBGJ is down 100.0% and TMO is up 28.0% - TMO leads by 128.0 points.
- TMO has been more active in the news (7 items in the past 4 weeks vs 4 for LBGJ).
- TMO has more recent analyst coverage (25 ratings vs 0 for LBGJ).
- Company
- Li Bang International Corporation Inc.
- Thermo Fisher Scientific Inc
- Price
- -
- -
- Market cap
- $1.2M
- $257.53B
- 1M return
- -15.54%
- +4.77%
- 1Y return
- -99.99%
- +28.01%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 4
- 7
- Recent ratings
- 0
- 25
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest LBGJ
- SEC Form 6-K filed by Li Bang International Corporation Inc.
- SEC Form 6-K filed by Li Bang International Corporation Inc.
- Li Bang International Corporation Inc. Announces Results of September 2026 Extraordinary General Meeting
- LI BANG INTERNATIONAL CORPORATION INC. Announces Adjournment of Extraordinary General Meeting
- SEC Form 6-K filed by Li Bang International Corporation Inc.
- Director Li Funa bought $51,299 worth of Class B ordinary shares (15,088 units at $3.40) (SEC Form 4)
- Chief Executive Officer Huang Feng bought $248,700 worth of Class B ordinary shares (73,147 units at $3.40) (SEC Form 4)
- SEC Form 6-K filed by Li Bang International Corporation Inc.
- SEC Form 6-K filed by Li Bang International Corporation Inc.
- Large owner Hrt Financial Lp sold $30,413 worth of shares (1,086,186 units at $0.03), decreasing direct ownership by 88% to 148,795 units (SEC Form 4)
Latest TMO
- SEC Form 4 filed by Director Weisler Dion J
- SEC Form 4 filed by Director Sperling Scott M
- SEC Form 4 filed by Director Lynch Karen S
- SEC Form 4 filed by Director Johnson Jennifer M
- SEC Form 4 filed by Director Keith R. Alexandra
- Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, October 21, 2026
- Thermo Fisher Scientific Launches Gibco™ CHO-K1 Catalog Panel Media and Feed to Accelerate Biologics Development
- Thermo Fisher upgraded by UBS with a new price target
- CLSA initiated coverage on Thermo Fisher with a new price target
- Executive Vice President Shafer Michael D covered exercise/tax liability with 790 shares, decreasing direct ownership by 4% to 20,204 units (SEC Form 4)